BridgeMD
New treatment option for Mobile Applications
Official title Use of a Comprehensive, Mobile Application to Assist Cancer Patients With Diet, Nutrition and Activity
ClinicalTrials.gov ID: NCT06860425
What this study is testing
- What it's testing
- The overarching purpose of this study is to assess whether patients will use the app throughout treatment on a regular basis, as the ultimate goal is to provide an educational platform that can impact patient behaviors and understanding towards health.
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Diagnosis of invasive malignancy of the brain, head and neck region, lung, breast (DCIS and invasive disease allowed), prostate, gastrointestinal...
- Planned to receive, or have received, radiation therapy treatment with curative intent
- Note: Patients undergoing systemic therapy are eligible
- Note: Any dose/fractionation of curative-intent radiation therapy is eligible
- Patients must have a smartphone or other device with the ability to receive text messages, download and use mobile applications
You likely can't join if
- Metastatic cancer
- Undergoing treatment with palliative intent
- Poorly controlled diabetes (defined as fasting glucose level \> 200 mg/dL despite attempts to improve glucose control by fasting duration and...
- Uncontrolled hypertension
- Any medical condition requiring fluid restriction or nutrient restrictions
See the full eligibility criteria
- Diagnosis of invasive malignancy of the brain, head and neck region, lung, breast (DCIS and invasive disease allowed), prostate, gastrointestinal system or gynecological region
- Planned to receive, or have received, radiation therapy treatment with curative intent
- Note: Patients undergoing systemic therapy are eligible
- Note: Any dose/fractionation of curative-intent radiation therapy is eligible
- Patients must have a smartphone or other device with the ability to receive text messages, download and use mobile applications
- Eastern Cooperative Oncology Group (ECOG) performance status 0-2
- Ability to read and write in English
- Provide written informed consent to participate in the study o NOTE: Patients enrolled on another clinical trial are eligible
- Metastatic cancer
- Undergoing treatment with palliative intent
- Poorly controlled diabetes (defined as fasting glucose level \> 200 mg/dL despite attempts to improve glucose control by fasting duration and adjustment of medications)
- Uncontrolled hypertension
- Any medical condition requiring fluid restriction or nutrient restrictions
The study team makes the final eligibility decision.
Where it's taking place
- The Bronx, New York, United States
Compensation & support
Compensation mentioned.
ClinicalTrials.gov doesn't provide a reliable structured field for payment or travel support - confirm details with the study team.
Questions & answers
Do participants get paid in this trial?
This study's listing includes signals that participants may be compensated or receive a stipend. Amounts vary and are set by the study team - confirm the details with them.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include The Bronx, New York, United States. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.